ab 19 November 2025 Global Research Micron Technology Inc Raise PT Again To $275 As Shortages Likely Persist Summary As it is about to go into quiet period, MU offered incremental color on the status of its business with commentary that was very much consistent with our latest round of industry checks – but did not positively pre-announce FQ1 (Nov). MU's view on the duration of supply tightness has extended versus 3mos ago (now through CYE2026) and it is now fully booked out on HBM supply through CYE2026. O ...

Core Viewpoint - CVS Health is experiencing a significant rebound, with shares rising 77% this year due to improved financial results, but still faces challenges in underperforming business segments [1][2]. Financial Performance - CVS Health reported a record revenue of $102.9 billion in the third quarter, a 7.8% increase compared to the same quarter in 2024 [4]. - Adjusted operating income reached $3.5 billion, reflecting a 35.8% year-over-year increase, with an operating margin of 3.4%, up from 2.7% the previous year [6]. - Non-GAAP earnings per share were $1.60, marking an almost 47% increase year-over-year [6]. Strategic Adjustments - The company is implementing a plan for at least $2 billion in cost savings, which includes store closures and workforce reductions [4]. - CVS plans to scale back its Medicare Advantage business and exit the Affordable Care Act's health insurance market, which are expected to improve profitability despite potentially lower overall revenue [8]. Valuation and Market Position - CVS Health's stock trades at 10.7 times forward earnings, significantly lower than the healthcare industry average of 17.1, making it an attractive investment opportunity [9]. - The company possesses a strong competitive advantage due to its extensive pharmacy network and long-term patient relationships [11]. Long-term Outlook - CVS is well-positioned to benefit from long-term trends such as an aging population, which is expected to increase healthcare spending [12]. - The stock offers a forward dividend yield of 3.4% with a reasonable cash payout ratio of 53.3%, appealing to long-term income seekers [13].

SBI’s standalone profit after tax rose 10% year-on-year to ₹20,160 crore in the second quarter, compared with ₹18,331 crore a year ago, beating estimates of a fall in profits. Asset quality improved, with net NPA declining to 0.42% from 0.53% a year earlier.“SBI’s robust set of numbers is among the best in the industry,” said Pankaj Pandey, head of fundamental research at ICICI Direct. “Even excluding the one-time gains from the Yes Bank stake sale, operational performance remains solid. Public sector bank ...

Core Insights - Aspo Plc's interim report for January 1 – September 30, 2025, indicates a strategic focus on profitability improvement and divestment activities to enhance financial performance [1] Financial Performance - Net sales for the group decreased to EUR 144.3 million in Q3 2025 from EUR 146.6 million in Q3 2024, while net sales from continuing operations decreased to EUR 108.1 million from EUR 113.7 million [5] - Comparable EBITA for the group increased to EUR 9.6 million in Q3 2025, representing 6.6% of net sales, compared to EUR 8.7 million and 5.9% in Q3 2024 [5][13] - For the first nine months of 2025, net sales grew by 5.9% to EUR 458.3 million, with comparable EBITA reaching EUR 27.5 million, up from EUR 21.1 million in the same period of 2024 [18][22] Business Segments - ESL Shipping reported a slight decline in comparable EBITA to EUR 3.5 million due to weak market conditions, particularly in the Coaster vessel segment [15] - Telko's comparable EBITA improved to EUR 4.8 million, driven by higher sales margins and the absence of acquisition-related expenses [16] - Leipurin's comparable EBITA for discontinued operations was EUR 1.9 million, with strong organic growth noted, particularly in Sweden [17] Strategic Actions - Aspo announced the divestment of its Leipurin business to Lantmännen for an enterprise value of EUR 63 million, expected to generate a gain of approximately EUR 16 million [20] - The divestment is part of Aspo's strategy to create two separate companies, Aspo Infra and Aspo Compounder, aimed at enhancing shareholder value [19] Guidance and Market Outlook - The company expects comparable EBITA for 2025 to be in the range of EUR 35–45 million, reflecting ongoing profitability improvement initiatives [6] - The operating environment is anticipated to remain challenging due to geopolitical uncertainties and global trade tensions, although increased defense and infrastructure spending in Europe may support recovery [7] Key Financial Ratios - Comparable return on equity (ROE) for the group was 13.4% for the first nine months of 2025, compared to 7.8% in the same period of 2024 [22] - The net debt to comparable EBITDA ratio increased to 3.9, attributed to hybrid bond repayments and investments in Green Coaster vessels [21]

Key Points The cancer-focused biotech surprised on the upside for both revenue and profitability in its latest reported quarter. Revenue rose by almost 40% year over year in that period. 10 stocks we like better than Guardant Health › Guardant Health (NASDAQ: GH) unveiled its latest set of quarterly results on Thursday, and the biotech's encouraging performance gave the stock significant upward momentum. The company's shares were up by 28% week to date as of early Friday morning, according to data c ...

Core Insights - Nxera Pharma has received a manufacturing approval partial amendment for QUVIVIQ® (daridorexant) 25 and 50 mg, which was launched in Japan in December 2024 for chronic insomnia treatment [1][2] - The company aims to establish a second API manufacturing site in Asia to meet the growing demand for QUVIVIQ® across the Asia-Pacific region, which is expected to reduce manufacturing costs and improve profitability starting in 2027 [2][6] - Nxera has set a 2030 Vision with sales exceeding JPY 50 billion and a profit margin exceeding 30%, supported by ongoing cost reduction initiatives [3] Manufacturing and Cost Reduction - Nxera submitted an application to Japan's Ministry of Health, Labour and Welfare for a partial amendment to add a manufacturing site in Asia, which will enhance supply resilience and reduce costs [2][6] - The company has planned three major projects for cost reduction, with one project completed and the remaining two expected to be finished by the end of 2028 [3] Commercial Partnerships and Sales Forecast - Nxera entered a commercial partnership with Shionogi & Co., Ltd. for the distribution and sales of QUVIVIQ® in Japan, with Shionogi forecasting JPY 2.5 billion in sales for the fiscal year ending March 2026 [4] - Nxera's sales forecast for QUVIVIQ® for the fiscal year ending December 2025 is between JPY 4.0 billion and JPY 5.0 billion [4] Future Developments - Nxera has entered a license, supply, and commercialization agreement with Holling Bio-Pharma Corp. for daridorexant in Taiwan, indicating expansion into new markets [5] - The company is focused on enhancing its capacity to respond to increased demand and aims to implement further cost reduction measures beyond 2029 [6]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported EBITDA of $313 million on net sales of $2.8 billion, with a loss of $38 million or $0.29 per share, reflecting a decrease in sales and EBITDA compared to Q2 2025 [7][14] - The loss in Q3 2025 was $26 million higher than in Q2 2025, primarily due to lower average sales prices, especially in PVC resin [14][21] - The company recorded a non-cash impairment charge of $727 million for goodwill associated with its North American chlorovinyls business unit [4][10] Business Line Data and Key Metrics Changes - The Housing and Infrastructure Products (HIP) segment delivered EBITDA of $215 million on $1.1 billion of sales, with sales volumes 6% lower compared to Q2 2025 [16][17] - The Performance and Essential Materials (PEM) segment reported sales of $1.7 billion, down $46 million from Q2 2025, driven by a 4% decline in average sales price [20][21] - HIP's EBITDA margin declined to 20% due to lower sales volume and period-related expenses, while PEM's EBITDA fell to $90 million compared to $297 million in Q3 2024 [17][22] Market Data and Key Metrics Changes - North American residential construction demand has softened in 2025, impacting sales volume in the HIP segment, although total sales remained comparable to 2024 [7][8] - The company noted a shift in sales mix towards lower-priced products in the HIP segment due to affordability issues faced by home buyers [8][20] - The global demand for PEM products, particularly PVC resins, has softened, contributing to a challenging macroeconomic environment [10][21] Company Strategy and Development Direction - The company is focused on a three-pillar strategy to improve PEM's performance: enhancing plant reliability, reducing costs, and optimizing the manufacturing footprint [10][11][28] - The HIP segment aims for long-term organic sales growth of 5% to 7% per annum, supported by new product innovations and strategic acquisitions [25][27] - The acquisition of ACI is expected to expand the company's global compound business and access to new markets, particularly in automotive and electrical sectors [9][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term growth outlook for the HIP segment despite current affordability headwinds in the housing market [8][20] - The company anticipates that the global supply-demand imbalance will improve, which will positively impact the chlorovinyls business in the medium to long term [10][70] - Management highlighted the importance of cost reduction actions and improved operational reliability to return the PEM segment to profitability [15][28] Other Important Information - The company expects total capital expenditures for 2025 to be approximately $900 million and has achieved $115 million towards its structural savings target for the year [23][22] - The company has a cash and investments balance of $2.1 billion and total debt of $4.7 billion as of September 30, 2025 [22] Q&A Session Summary Question: How will the weakening polyethylene market affect earnings in Q4? - Management acknowledged a slight weakening in polyethylene prices but expects stable operating efficiency and demand [32][33] Question: Is the board committed to the current portfolio structure? - Management believes in the synergy of the combined businesses and expects improvements in the PVC business as market conditions stabilize [34][36] Question: What is the near and mid-term outlook for PVC? - Management noted challenges in the chlorovinyl chain but is focused on cost reductions and improving reliability to enhance profitability [40][41] Question: Can you provide details on the ACI acquisition's expected performance? - The ACI business is expected to have good margins and synergies with the existing compounds business, aligning with HIP segment margins [42][43] Question: Why is the HIP guidance lower? - The lower guidance is attributed to a shift in product mix and period-related costs, but management remains optimistic about 2026 construction activity [47][50] Question: What is the outlook for the caustic soda market? - The market is well supplied, and pricing is expected to remain stable [52] Question: How is the company addressing affordability issues in the housing market? - The company is adjusting its product mix to include more affordable options to meet builder needs [104]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported EBITDA of $313 million on net sales of $2.8 billion, with a loss of $38 million or $0.29 per share, reflecting a $26 million increase in loss compared to Q2 2025 primarily due to lower average sales prices, especially in PVC resin [6][16][24] - The company recorded a non-cash impairment charge of $727 million related to goodwill associated with its North American chlorovinyls business unit, which significantly impacted financial results [3][10][16] Business Line Data and Key Metrics Changes - The Housing and Infrastructure Products (HIP) segment delivered EBITDA of $215 million on $1.1 billion of sales, with sales volumes 6% lower compared to Q2 2025, but comparable to Q3 2024 [18][19] - The Performance and Essential Materials (PEM) segment saw sales of $1.7 billion, a decrease of $46 million from Q2 2025, driven by a 4% decline in average sales price, which more than offset a 1% increase in sales volume [21][22][24] Market Data and Key Metrics Changes - North American residential construction demand has softened in 2025, impacting the HIP segment, although sales volumes remained stable compared to 2024 [6][8] - The global demand for PEM products, particularly PVC resins, has softened, contributing to a challenging macroeconomic environment and an extended trough in the chlorovinyl chain [10][24] Company Strategy and Development Direction - The company is focused on a three-pillar strategy to improve PEM's performance: enhancing plant reliability, reducing costs, and optimizing the manufacturing footprint [11][13][29] - The company is committed to long-term growth in the HIP segment, supported by investments in new facilities and acquisitions, such as the ACI acquisition, which will expand its global compound business [9][21][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term growth outlook for the HIP segment despite current affordability challenges in the housing market, citing ongoing investments and a solid pipeline of new products [8][27] - The company anticipates that the global supply-demand imbalance will improve over time, which will positively impact the chlorovinyls business [10][29] Other Important Information - The company expects total capital expenditures for 2025 to be approximately $900 million and has achieved $115 million towards its structural savings target of $150 million to $175 million for 2025 [25][24] - The company has a cash and investments balance of $2.1 billion and total debt of $4.7 billion as of September 30, 2025 [24] Q&A Session Summary Question: How will the weakening polyethylene market affect earnings in Q4? - Management acknowledged a slight weakening in polyethylene prices but expects stable operating efficiency and will strive to create value in that segment [35][36] Question: Is the board committed to the current portfolio structure? - Management believes in the synergy of the combined businesses and expects improvements in the PVC business as market conditions stabilize [38][39] Question: What is the near and mid-term outlook for PVC? - Management noted challenges in the chlorovinyl chain but is focused on cost reductions and improving reliability to return to acceptable financial returns [44][46] Question: Can you provide details on the ACI acquisition? - The ACI business is expected to have good margins and synergies with the existing compounds business, enhancing overall performance [48][49] Question: What are the reasons for the revision to HIP guidance? - The revision was due to a shift in product mix and non-recurring period-related costs, but management remains optimistic about the repair and remodeling segment [53][55] Question: How is the company addressing affordability issues in the housing market? - The company is adjusting its product mix to include more affordable options to meet customer needs [112]

Core Insights - FormFactor, Inc. reported Q3 fiscal 2025 revenues of $202.7 million, a 3.5% increase from Q2 2025 but a 2.5% decrease from Q3 2024 [1] - The company expects to deliver higher results in Q4 2025, building on the profitability improvement initiatives [7] Financial Performance - GAAP net income for Q3 2025 was $15.7 million, or $0.20 per diluted share, compared to $9.1 million, or $0.12 per diluted share in Q2 2025, and $18.7 million, or $0.24 per diluted share in Q3 2024 [3] - Non-GAAP net income for Q3 2025 was $25.7 million, or $0.33 per diluted share, compared to $21.2 million, or $0.27 per diluted share in Q2 2025, and $27.2 million, or $0.35 per diluted share in Q3 2024 [4] - Gross margin for Q3 2025 was 39.8%, up from 37.3% in Q2 2025 but down from 40.7% in Q3 2024 [3] Cash Flow and Operating Activities - GAAP net cash provided by operating activities for Q3 2025 was $27.0 million, compared to $18.9 million in Q2 2025 and $26.7 million in Q3 2024 [5] - Free cash flow for Q3 2025 was $19.7 million, a significant recovery from negative $47.1 million in Q2 2025 [5] Outlook - For Q4 2025, FormFactor anticipates revenues of approximately $210 million, with a gross margin of around 40.0% [7] - The company expects continued improvement in profitability and gross margins due to ongoing initiatives [2][8]

Summary of China Southern Airlines 3Q25 Earnings Call Company Overview - **Company**: China Southern Airlines (CSA) - **Ticker**: 1055.HK - **Industry**: Transportation & Infrastructure - **Market Cap**: Rmb108,739.8 million - **Current Share Price**: HK$4.65 - **Price Target**: HK$5.33, indicating a 15% upside potential [5][7] Key Financial Highlights - **Net Profit**: Rmb3.8 billion in 3Q25, representing a 20% year-over-year increase [2][7] - **Profit Before Tax (PBT)**: Rmb5.8 billion, up 30% YoY, excluding Rmb0.3 billion of foreign exchange loss [2][7] - **Revenue**: Rmb51.4 billion in 3Q25, a 3% YoY increase [7] - **Operating Cash Flow**: Rmb18 billion in 3Q25, a 62% YoY increase, contributing to a total of Rmb32 billion for the first nine months of 2025 [7] - **Capital Expenditure (Capex)**: Rmb8 billion in 9M25, indicating positive free cash flow after lease payments [7] Operational Metrics - **Available Seat Kilometers (ASK)**: Increased by 5.7% YoY [7] - **Revenue Passenger Kilometers (RPK)**: Increased by 6.2% YoY, reaching 115% of 2019 levels [7] - **Unit Cost (including fuel)**: Decreased by 3% YoY, but increased by 3% compared to 3Q19 [7] Market Outlook - **Profitability**: High probability of continued YoY profitability improvement in 4Q25, with expectations of full-year profitability [7] - **Yield Trends**: Anticipated low-single-digit YoY drop in passenger yield in 3Q25, supported by strong long-haul international yields and improved domestic yields in September [7] Valuation and Risks - **Valuation Methodology**: Utilizes probability-weighted P/BV multiples with different scenarios (bull, base, bear) for 2026 estimates [13] - **Bull Case P/BV**: 3.2x; Base Case P/BV: 1.9x; Bear Case P/BV: 1.0x [13] - **Upside Risks**: Include yield improvements from higher ticket prices, faster-than-expected traffic recovery, and significant RMB appreciation [13] - **Downside Risks**: Include weak travel demand and RMB depreciation [13] Analyst Ratings - **Stock Rating**: Overweight [5] - **Industry View**: In-Line [5] Additional Insights - **Earnings Estimates**: Morgan Stanley's earnings estimates for CSA are above consensus for 2026-2027 [7] - **Market Sentiment**: The overall sentiment remains bullish on Chinese airlines, with CSA-H rated as Overweight and CSA-A rated as Equal-weight [7] This summary encapsulates the key points from the earnings call, highlighting the financial performance, operational metrics, market outlook, and valuation considerations for China Southern Airlines.